Literature DB >> 9675146

Novel 31-amino-acid-length endothelins cause constriction of vascular smooth muscle.

F Kishi1, K Minami, N Okishima, M Murakami, S Mori, M Yano, Y Niwa, Y Nakaya, H Kido.   

Abstract

We have reported that human chymase specifically cleaves big endothelins (ETs) at the Try31-Gly32 bond, and produces novel trachea-constricting 31-amino-acid-length ETs, ETs(1-31). In this study, we investigated the effect of synthetic ETs(1-31) on the contractile activity toward porcine coronary arteries and rat aortae. Although ETs(1-31) exhibited less potent vasoconstrictile activity in these tissues than 21-amino-acid-length ETs(1-21), or a similar extent, ET-1(1-31) caused significantly slower-developing and longer-lasting contraction than ETs(1-21). The ETA receptor antagonist, BQ485, completely inhibited the activity of ET-1(1-31). The ETB receptor antagonist, BQ788, also inhibited the activity of ET-1(1-31) toward rat aortae more efficiently than that ET-1(1-21). Therefore, trachea-constricting peptides ETs(1-31) play roles as vasoconstrictors in a different manner from ETs(1-21). Copyright 1998 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9675146     DOI: 10.1006/bbrc.1998.8980

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  9 in total

1.  Enzymatic pathways involved in the generation of endothelin-1(1-31) from exogenous big endothelin-1 in the rabbit aorta.

Authors:  Carlos R Tirapelli; Marie-Helene Fecteau; Jean-Claude Honore; Eurode Legros; Fernand Gobeil; Pedro D'Orleans-Juste
Journal:  Br J Pharmacol       Date:  2006-04-24       Impact factor: 8.739

Review 2.  Privileged frameworks from snake venom.

Authors:  T A Reeks; B G Fry; P F Alewood
Journal:  Cell Mol Life Sci       Date:  2015-02-19       Impact factor: 9.261

Review 3.  The therapeutic potential of endothelin receptor antagonists in cardiovascular disease.

Authors:  M Barton; W Kiowski
Journal:  Curr Hypertens Rep       Date:  2001-08       Impact factor: 5.369

4.  Ambrisentan reduces pulmonary arterial hypertension but does not stimulate alveolar and vascular development in neonatal rats with hyperoxic lung injury.

Authors:  Gerry T M Wagenaar; El Houari Laghmani; Yvonne P de Visser; Rozemarijn M A Sengers; Paul Steendijk; Hans J Baelde; Frans J Walther
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2013-01-04       Impact factor: 5.464

5.  Vasoconstrictor activity of novel endothelin peptide, ET-1(1 - 31), in human mammary and coronary arteries in vitro.

Authors:  J J Maguire; R E Kuc; A P Davenport
Journal:  Br J Pharmacol       Date:  2001-11       Impact factor: 8.739

Review 6.  Regulation of sodium transport in the proximal tubule by endothelin.

Authors:  Ye Zhang; Pedro A Jose; Chunyu Zeng
Journal:  Contrib Nephrol       Date:  2011-08-30       Impact factor: 1.580

7.  Pressor and pulmonary responses to ET-1(1-31) in guinea-pigs.

Authors:  Jean-Claude Honoré; Mirco Plante; Ghassan Bkaily; Giles A Rae; Pedro D'Orléans-Juste
Journal:  Br J Pharmacol       Date:  2002-07       Impact factor: 8.739

8.  Endothelins and their inhibition in the human skin microcirculation: ET[1-31], a new vasoconstrictor peptide.

Authors:  Stephen J Leslie; Mamun Q Rahman; Martin A Denvir; David E Newby; David J Webb
Journal:  Br J Clin Pharmacol       Date:  2004-06       Impact factor: 4.335

Review 9.  Endothelial dysfunction and atherosclerosis: endothelin receptor antagonists as novel therapeutics.

Authors:  M Barton
Journal:  Curr Hypertens Rep       Date:  2000-02       Impact factor: 4.592

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.